在高需求低资源急诊科实施丁丙诺啡启动项目:一项非随机对照试验
这项多中心实施研究采用参与式行动研究法,在3家既往未启动丁丙诺啡的急诊科开发并优化了急诊启动丁丙诺啡及转诊的本地化临床路径。通过混合方法评估可行性、可接受性和有效性,主要实施结局为候选患者中接受急诊启动丁丙诺啡的比例,次要结局为30天治疗参与。结果显示3个月内各站点均启动项目,6个月评估期内2522次涉及阿片类使用的就诊中识别出134名候选患者,112名(85.1%;95%CI 79.7%至90.4%)接受了急诊启动的丁丙诺啡;40名入组患者中49.0%(95%CI 35.6%至62.5%)在30天时确认参与成瘾治疗,自报过量事件下降4倍(OR 4.03;95%CI 1.27至12.75),急诊临床医生准备度中位数从1.92/10升至6.95/10(升高5.02;95%CI 3.56至6.47)。
要点
- 实施促进法在3家高需求低资源急诊科中,3个月内均成功启动丁丙诺啡项目。
- 6个月评估期内2522次涉及阿片类使用的就诊中,134名为丁丙诺啡候选患者,其中112名(85.1%;95%CI 79.7%至90.4%)接受了急诊启动的丁丙诺啡。
- 40名入组患者中,49.0%(95%CI 35.6%至62.5%)在30天时确认参与成瘾治疗,26名(68.4%)报告至少一次治疗就诊。
- 自报过量事件下降4倍(OR 4.03;95%CI 1.27至12.75)。
- 急诊临床医生准备度中位数从1.92/10升至6.95/10,升高5.02(95%CI 3.56至6.47)。
适用人群与场景
- 3家既往未启动丁丙诺啡的急诊科,位于农村和城市高需求、资源有限且人员结构不同的环境。
- 研究纳入的40名患者参与者需符合:英语使用者、病情稳定、有定位信息、非囚犯。
处置流程与药物剂量
- 通过实施促进法,采用参与式行动研究法开发、引入并优化各站点特定的急诊启动丁丙诺啡及转诊临床路径。
研究设计与关键结果
- 研究类型:多中心非随机对照实施研究,采用混合方法形成性评估(焦点小组/访谈、前后调查)及患者病历和30天结局。
- 主要实施结局:6个月评估期内2522次涉及阿片类使用的就诊中,134名为急诊丁丙诺啡候选患者,112名(85.1%;95%CI 79.7%至90.4%)接受了急诊启动的丁丙诺啡。
- 52名(41.6%)执业者启动了丁丙诺啡给药。
- 主要次要结局:40名入组患者中,49.0%(95%CI 35.6%至62.5%)在30天时确认参与成瘾治疗;26名(68.4%)报告至少一次治疗就诊。
- 自报过量事件下降4倍(OR 4.03;95%CI 1.27至12.75)。
- 急诊临床医生准备度中位数从1.92/10升至6.95/10,升高5.02(95%CI 3.56至6.47)(n(前)=80,n(后)=83)。
证据类型、等级与局限
- 证据类型:多中心非随机对照实施研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 实施促进法可使高需求低资源急诊科在3个月内快速启动急诊丁丙诺啡项目,候选患者中85.1%接受了急诊启动的丁丙诺啡。
- 作者认为,该实施促进法能够在异质性急诊环境中有效实施急诊丁丙诺啡项目,并与有前景的实施结局和探索性患者层面结局相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: We hypothesized that implementation facilitation would enable us to rapidly and effectively implement emergency department (ED)-initiated buprenorphine programs in rural and urban settings with high-need, limited resources and dissimilar staffing structures.
METHODS: This multicenter implementation study employed implementation facilitation using a participatory action research approach to develop, introduce, and refine site-specific clinical protocols for ED-initiated buprenorphine and referral in 3 EDs not previously initiating buprenorphine. We assessed feasibility, acceptability, and effectiveness by triangulating mixed-methods formative evaluation data (focus groups/interviews and pre/post surveys involving staff, patients, and stakeholders), patients' medical records, and 30-day outcomes from a purposive sample of 40 buprenorphine-receiving patient-participants who met research eligibility criteria (English-speaking, medically stable, locator information, nonprisoners). We estimated the primary implementation outcome (proportion receiving ED-initiated buprenorphine among candidates) and the main secondary outcome (30-day treatment engagement) using Bayesian methods.
RESULTS: Within 3 months of initiating the implementation facilitation activities, each site implemented buprenorphine programs. During the 6-month programmatic evaluation, there were 134 ED-buprenorphine candidates among 2,522 encounters involving opioid use. A total of 52 (41.6%) practitioners initiated buprenorphine administration to 112 (85.1%; 95% confidence interval [CI] 79.7% to 90.4%) unique patients. Among 40 enrolled patient-participants, 49.0% (35.6% to 62.5%) were engaged in addiction treatment 30 days later (confirmed); 26 (68.4%) reported attending one or more treatment visits; there was a 4-fold decrease in self-reported overdose events (odds ratio [OR] 4.03; 95% CI 1.27 to 12.75). The ED clinician readiness increased by a median of 5.02 (95% CI: 3.56 to 6.47) from 1.92/10 to 6.95/10 (n(pre)=80, n(post)=83).
CONCLUSIONS: The implementation facilitation enabled us to effectively implement ED-based buprenorphine programs across heterogeneous ED settings rapidly, which was associated with promising implementation and exploratory patient-level outcomes.
参考来源
- McCormack RP, Rotrosen J, Gauthier P, et al. Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial. Ann Emerg Med. 2023. PMID: 37140493. doi:10.1016/j.annemergmed.2023.02.013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。